← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...

MeiraGTx Holdings plc (MGTX) 10-Year Financial Performance & Capital Metrics

MGTX • • Industrial / General
HealthcareBiotechnologyRare Genetic DiseasesGene Therapy & Rare Diseases
AboutMeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. MeiraGTx Holdings plc was incorporated in 2015 and is based in New York, New York.Show more
  • Revenue $33M +137.4%
  • EBITDA -$151M -22.7%
  • Net Income -$148M -75.9%
  • EPS (Diluted) -2.12 -42.3%
  • Gross Margin 28.51% -71.5%
  • EBITDA Margin -454.89% +48.3%
  • Operating Margin -493.44% +49.5%
  • Net Margin -444.1% +25.9%
  • ROE -143.48% -118.5%
  • ROIC -167.75% -56.9%
  • Debt/Equity 1.25 +93.5%
  • Interest Coverage -12.37 -19.6%
Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

  • ✓Strong 5Y sales CAGR of 20.1%

✗Weaknesses

  • ✗Weak Piotroski F-Score: 2/9
  • ✗Negative free cash flow
  • ✗Shares diluted 23.6% in last year
  • ✗Low asset turnover indicates capital-intensive operations

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-
5Y20.15%
3Y-4.07%
TTM96.83%

Profit (Net Income) CAGR

10Y-
5Y-
3Y-
TTM-91.31%

EPS CAGR

10Y-
5Y-
3Y-
TTM-61.07%

ROCE

10Y Avg-95.43%
5Y Avg-44.07%
3Y Avg-57.68%
Latest-70.08%

Peer Comparison

Gene Therapy & Rare Diseases
Select Columns
Size & Scale
Valuation
Per Share
Growth
Profitability
Quality & Returns
Safety & Leverage
TTM Growth
Famous Investor Metrics
Dividends
Latest Quarter
Momentum & Returns
Total Return (DRIP)
Technical
Volume & Trading
Shares & Dilution
Sector-Specific
NameMarket CapCurrent PriceP/E RatioRevenue Growth 1YNet MarginROEFCF YieldDebt/Equity
KRYSKrystal Biotech, Inc.8.18B282.0194.00473.02%53.3%17.48%1.46%0.01
BMRNBioMarin Pharmaceutical Inc.10.58B55.0724.9217.97%16.82%8.59%4.49%0.11
SRPTSarepta Therapeutics, Inc.2.23B21.319.1152.97%-11.25%-20.57%0.88
RAREUltragenyx Pharmaceutical Inc.2.27B23.50-3.7429.01%-91.95%-35.88%0.15
DYNDyne Therapeutics, Inc.2.7B16.42-4.87-61.26%0.04
TVTXTravere Therapeutics, Inc.2.54B28.40-6.9660.55%-20.32%-120.36%6.80
BEAMBeam Therapeutics Inc.3.25B32.05-7.00-83.18%-7.44%-42.92%0.22
SLNOSoleno Therapeutics, Inc.2.25B41.95-9.58-79.5%-15.85%0.22

Profit & Loss

Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Sales/Revenue+00013.29M15.56M37.7M15.92M14.02M33.28M
Revenue Growth %----0.17%1.42%-0.58%-0.12%1.37%
Cost of Goods Sold+243.08K679.18K2.05M0000023.79M
COGS % of Revenue--------0.71%
Gross Profit+-243.08K-679.18K-2.05M13.29M15.56M37.7M15.92M14.02M9.49M
Gross Margin %---1%1%1%1%1%0.29%
Gross Profit Growth %--1.79%-2.02%7.47%0.17%1.42%-0.58%-0.12%-0.32%
Operating Expenses+20.06M31.68M78.1M71.56M78.12M110.46M132.28M151.08M173.7M
OpEx % of Revenue---5.38%5.02%2.93%8.31%10.78%5.22%
Selling, General & Admin6.03M9.33M44.48M46.68M44.21M43.77M46.55M47.29M54.22M
SG&A % of Revenue---3.51%2.84%1.16%2.92%3.37%1.63%
Research & Development14.04M22.36M33.62M24.88M33.91M66.69M85.72M103.78M119.48M
R&D % of Revenue---1.87%2.18%1.77%5.38%7.4%3.59%
Other Operating Expenses0-553.5K83.08K000000
Operating Income+-20.06M-31.68M-78.1M-58.27M-62.55M-72.76M-116.36M-137.06M-164.21M
Operating Margin %----4.38%-4.02%-1.93%-7.31%-9.78%-4.93%
Operating Income Growth %--0.58%-1.47%0.25%-0.07%-0.16%-0.6%-0.18%-0.2%
EBITDA+-19.82M-31.01M-76.05M-56.03M-58.38M-64.89M-107.75M-123.33M-151.38M
EBITDA Margin %----4.22%-3.75%-1.72%-6.77%-8.8%-4.55%
EBITDA Growth %--0.56%-1.45%0.26%-0.04%-0.11%-0.66%-0.14%-0.23%
D&A (Non-Cash Add-back)243.08K679.18K2.05M2.24M4.17M7.87M8.6M13.73M12.83M
EBIT-20.06M-31.68M-78.1M-54.7M-57.85M-79.27M-124.67M-70.78M-134.52M
Net Interest Income+6.63K-16.79K19.98K321.99K1.14M-76K-4.17M-10.97M-9.13M
Interest Income32.07K26.07K53.41K370.6K1.28M212K777K2.27M4.14M
Interest Expense25.44K42.86K33.43K48.61K139.2K288K4.95M13.24M13.27M
Other Income/Expense272.17K640.19K-5.24M3.52M4.56M-6.8M-13.26M53.03M16.42M
Pretax Income+-19.79M-31.04M-83.34M-54.75M-57.99M-79.56M-129.62M-84.03M-147.79M
Pretax Margin %----4.12%-3.73%-2.11%-8.14%-5.99%-4.44%
Income Tax+00-474.39K000000
Effective Tax Rate %0.98%1%0.99%1%1%1%1%1%1%
Net Income+-19.49M-31.04M-82.87M-54.75M-57.99M-79.56M-129.62M-84.03M-147.79M
Net Margin %----4.12%-3.73%-2.11%-8.14%-5.99%-4.44%
Net Income Growth %--0.59%-1.67%0.34%-0.06%-0.37%-0.63%0.35%-0.76%
Net Income (Continuing)-19.79M-31.04M-82.87M-54.75M-57.99M-79.56M-129.62M-84.03M-147.79M
Discontinued Operations000000000
Minority Interest000000000
EPS (Diluted)+-1.01-3.62-4.37-1.58-1.43-1.63-3.16-1.49-2.12
EPS Growth %--2.58%-0.21%0.64%0.09%-0.14%-0.94%0.53%-0.42%
EPS (Basic)-1.01-3.62-4.37-1.58-1.43-1.63-3.16-1.49-2.12
Diluted Shares Outstanding19.24M8.57M18.95M33.16M37.72M44.14M45.18M56.49M69.82M
Basic Shares Outstanding19.24M8.57M18.95M33.16M37.72M44.14M45.18M56.49M69.82M
Dividend Payout Ratio---------

Balance Sheet

Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Total Current Assets+19.09M11.48M74.65M268.98M272.58M183.24M154.34M159.62M123.52M
Cash & Short-Term Investments17.48M8.55M68.08M227.23M209.52M137.7M115.52M129.57M103.66M
Cash Only17.48M8.55M68.08M227.23M209.52M137.7M115.52M129.57M103.66M
Short-Term Investments000000000
Accounts Receivable00037.11M55.41M35.02M29.02M23.41M10.63M
Days Sales Outstanding---1.02K1.3K339.02665.41609.72116.57
Inventory00000000385K
Days Inventory Outstanding--------5.91
Other Current Assets400.96K965.23K4.63M170.59K564.44K2.42M1.67M1.02M2.02M
Total Non-Current Assets+3.46M14.38M22.24M54.91M91.12M136.92M163.9M167.12M146.23M
Property, Plant & Equipment3.02M14.26M22.01M52.86M87.12M126.29M154.09M156.24M135.65M
Fixed Asset Turnover---0.25x0.18x0.30x0.10x0.09x0.25x
Goodwill000000000
Intangible Assets000777.65K2.97M2.57M2.08M1.12M821K
Long-Term Investments444.84K123.38K123.38K123.38K06.66M6.33M6.77M6.75M
Other Non-Current Assets00105.08K1.15M1.03M1.4M1.4M3M3.01M
Total Assets+22.55M25.85M96.89M323.89M363.7M320.16M318.24M326.74M269.75M
Asset Turnover---0.04x0.04x0.12x0.05x0.04x0.12x
Asset Growth %-0.15%2.75%2.34%0.12%-0.12%-0.01%0.03%-0.17%
Total Current Liabilities+6.04M21.4M15.5M49.2M54.15M68.13M82.07M67.08M60.78M
Accounts Payable1.47M7.06M3.04M3.76M7.13M15.35M16.62M16.04M23.59M
Days Payables Outstanding2.21K3.79K541-----361.85
Short-Term Debt01.44M27.2K1.67M2.58M0000
Deferred Revenue (Current)-6.01K1000K1000K1000K1000K1000K1000K1000K1000K
Other Current Liabilities1.96M2.68M6.14M11.23M17.09M6.03M16.23M41.28M12.1M
Current Ratio3.16x0.54x4.82x5.47x5.03x2.69x1.88x2.38x2.03x
Quick Ratio3.16x0.54x4.82x5.47x5.03x2.69x1.88x2.38x2.03x
Cash Conversion Cycle---------239.38
Total Non-Current Liabilities+33.65M51.82M336.48K83.89M70.99M66.64M118.43M121.49M141.14M
Long-Term Debt00000071.03M72.12M73.22M
Capital Lease Obligations5.46K34.3K7.1K21.5M19.67M20.36M17.33M12.95M7.52M
Deferred Tax Liabilities-588.49K-266.29K-201.26K195.05K213.72K196K186K00
Other Non-Current Liabilities33.64M51.78M329.38K1.65M1.81M3.03M2.44M2.4M2.82M
Total Liabilities39.69M73.22M15.84M133.09M125.14M134.76M200.5M188.57M201.92M
Total Debt+11.47K1.51M34.3K23.18M22.25M23.73M92.25M89.26M84.8M
Net Debt-17.47M-7.04M-68.05M-204.05M-187.27M-113.97M-23.27M-40.3M-18.86M
Debt / Equity--0.00x0.12x0.09x0.13x0.78x0.65x1.25x
Debt / EBITDA---------
Net Debt / EBITDA---------
Interest Coverage-788.70x-739.21x-2336.42x-1198.63x-449.37x-252.63x-23.53x-10.35x-12.37x
Total Equity+-17.14M-47.37M81.06M190.8M238.56M185.4M117.74M138.18M67.83M
Equity Growth %--1.76%2.71%1.35%0.25%-0.22%-0.36%0.17%-0.51%
Book Value per Share-0.89-5.534.285.756.324.202.612.450.97
Total Shareholders' Equity-17.14M-47.37M81.06M190.8M238.56M185.4M117.74M138.18M67.83M
Common Stock3423421.06K1.43K1.72K2K2K2K3K
Retained Earnings-34.38M-65.42M-148.29M-203.04M-261.03M-340.59M-470.2M-554.23M-702.02M
Treasury Stock000000000
Accumulated OCI-661.11K-2.02M293.67K-1.79M-4.9M-2.67M6.05M-1.44M-3.72M
Minority Interest000000000

Cash Flow

Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Cash from Operations+-14.37M-18.06M-58.89M20.04M-63.97M-10.53M-73.1M-105.36M-104.5M
Operating CF Margin %---1.51%-4.11%-0.28%-4.59%-7.52%-3.14%
Operating CF Growth %--0.26%-2.26%1.34%-4.19%0.84%-5.94%-0.44%0.01%
Net Income-19.79M-31.04M-82.87M-54.75M-57.99M-79.56M-129.62M-84.03M-147.79M
Depreciation & Amortization243.08K679.18K2.05M2.24M4.17M7.87M8.6M13.72M12.68M
Stock-Based Compensation2.81M2.96M17.88M15.93M18.42M20.78M28.62M27.72M25.19M
Deferred Taxes-261.82K-1.21M-474.39K000000
Other Non-Cash Items1.06M2.03M8.43M-105.01K4.08M9.1M9.67M-61.8M-24.22M
Working Capital Changes1.58M8.53M-3.92M56.73M-32.64M31.28M9.62M-983K29.64M
Change in Receivables000-32.29M-16.12M16.7M5.17M4.83M9.43M
Change in Inventory00000000-387K
Change in Payables453.13K4.73M-2.12M-8.68K1.57M13.35M3.74M2.33M10.74M
Cash from Investing+-2.59M-10.54M-11.26M-9.37M-37.02M-61.72M-44.96M34.03M23.48M
Capital Expenditures-2.59M-10.54M-11.26M-8.98M-34.89M-55.22M-44.96M-20.17M-4.96M
CapEx % of Revenue---0.68%2.24%1.46%2.82%1.44%0.15%
Acquisitions---------
Investments---------
Other Investing0000-2.13M0054.21M28.43M
Cash from Financing+20.76M19.34M130.04M148.23M82.73M1.71M95.2M84.02M54.53M
Debt Issued (Net)---------
Equity Issued (Net)---------
Dividends Paid000000000
Share Repurchases---------
Other Financing016.86M130.07M-6.94M-4.3M1.71M-4.8M-7.93M-4.86M
Net Change in Cash---------
Free Cash Flow+-16.96M-28.59M-70.15M11.06M-100.99M-65.75M-118.06M-125.54M-109.45M
FCF Margin %---0.83%-6.49%-1.74%-7.42%-8.96%-3.29%
FCF Growth %--0.69%-1.45%1.16%-10.13%0.35%-0.8%-0.06%0.13%
FCF per Share-0.88-3.34-3.700.33-2.68-1.49-2.61-2.22-1.57
FCF Conversion (FCF/Net Income)0.74x0.58x0.71x-0.37x1.10x0.13x0.56x1.25x0.71x
Interest Paid0001.46K3K139K329K13.05M12.03M
Taxes Paid000000000

Key Ratios

Metric201620172018201920202021202220232024
Return on Equity (ROE)---491.87%-40.28%-27.01%-37.53%-85.52%-65.67%-143.48%
Return on Invested Capital (ROIC)---450.13%--246.7%-88.93%-105.2%-106.89%-167.75%
Gross Margin---100%100%100%100%100%28.51%
Net Margin----411.87%-372.63%-211.03%-814.16%-599.46%-444.1%
Debt / Equity--0.00x0.12x0.09x0.13x0.78x0.65x1.25x
Interest Coverage-788.70x-739.21x-2336.42x-1198.63x-449.37x-252.63x-23.53x-10.35x-12.37x
FCF Conversion0.74x0.58x0.71x-0.37x1.10x0.13x0.56x1.25x0.71x
Revenue Growth----17.09%142.25%-57.77%-11.95%137.42%

Frequently Asked Questions

Growth & Financials

MeiraGTx Holdings plc (MGTX) reported $27.4M in revenue for fiscal year 2024.

MeiraGTx Holdings plc (MGTX) grew revenue by 137.4% over the past year. This is strong growth.

MeiraGTx Holdings plc (MGTX) reported a net loss of $168.7M for fiscal year 2024.

Dividend & Returns

MeiraGTx Holdings plc (MGTX) has a return on equity (ROE) of -143.5%. Negative ROE indicates the company is unprofitable.

MeiraGTx Holdings plc (MGTX) had negative free cash flow of $121.0M in fiscal year 2024, likely due to heavy capital investments.

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.